STOCKHOLM, Sweden, April 21, 2004 (PRIMEZONE) -- Artimplant and Carnegie Mellon University in research collaboration on Artelon(R) in bone applications.
Artimplant, a biomaterials and orthobiologics company based in Gothenburg, Sweden, and Carnegie Mellon University, Pittsburgh, Pennsylvania, has entered into a research agreement relating to Artimplant's proprietary degradable biomaterial ARTELON in bone applications.
The first phase of the pre-clinical research will examine the soft, porous ARTELON Scaffold without and in combination with autologous cells. A soft scaffold offers several new interesting possibilities in regenerating bone.
Previous preclinical and clinical studies with ARTELON as scaffold, fiber and film have shown excellent biocompatibility in both bone and soft tissue.
"We are enthusiastic about this collaboration. Artimplant's polyurethanes technology offers exciting potential in many orthopedic applications," said Professor Jeffrey Hollinger, at Carnegie Mellon's Bone Tissue Engineering Center.
"This initial collaboration with Carnegie Mellon, a premier global center of excellence in biomaterials research, provides a major opportunity for Artimplant, as it offers expertise and a natural expansion into specific applications in spine, maxillofacial, trauma and odontology," said CEO Tord Lendau of Artimplant.
Carnegie Mellon University, Center for Bone Tissue Engineering
The Bone Tissue Engineering Center is a collaborative program among Carnegie Mellon's College of Engineering, Mellon College of Science and Robotics Institute, with the University of Pittsburgh Medical Center, the University of Pittsburgh, Children's Hospital and Duquesne University. The center's mission is to develop technologies that will translate into safe and effective clinical therapies. The bone and cartilage clinical therapies will treat developmental deformities, ablative injuries, degenerative changes, tendon and ligament healing, hypoplastic fat and vascular insufficiencies. The center encourages the transfer of developed technologies and treatments to enable new biotechnology ventures providing jobs and regional economic development.
Artimplant AB
Artimplant's mission is to develop novel biodegradable materials and implants that meet the needs of patients, physicians and healthcare providers in orthopedics and other therapy areas. The company works together with global partners as a center of excellence in this development.
Artimplant's vision is to become the partner of choice in biomaterials for hard and soft tissue repair in multiple therapy areas.
Artimplant is a public company, listed on the Stockholm Exchange, O- list.
Nota Bene: Artelon(R) is a registered trade name in Europe. Registrations in the United States and Japan are pending.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/04/21/20040421BIT00120/wkr0001.doc
http://www.waymaker.net/bitonline/2004/04/21/20040421BIT00120/wkr0002.pdf